Latest Opaleye Management Inc. Stock Portfolio
$1.10Billion | No. of Holdings #58
Opaleye Management Inc. Performance
2026 Q2+33.08%
YTD+41.62%
2025+26.95%
About Opaleye Management Inc. and 13F Hedge Fund Stock Holdings
Opaleye Management Inc. is a hedge fund based in Boston, MA. On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Opaleye Management Inc. reported an equity portfolio of $1.1 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Opaleye Management Inc. are LQDA, ETON, HROW. The fund has invested 17.7% of it's portfolio in LIQUIDIA CORPORATION and 9.4% of portfolio in ETON PHARMACEUTICALS INC. <br><br> The fund managers got completely rid off PERSPECTIVE THERAPEUTICS INC, ASSERTIO HOLDINGS INC (ASRT) and SUTRO BIOPHARMA INC (STRO) stocks. They significantly reduced their stock positions in CG ONCOLOGY INC, SANUWAVE HEALTH INC (SNWV) and JADE BIOSCIENCES INC (AVTE). Opaleye Management Inc. opened new stock positions in IMMIX BIOPHARMA INC (IMMX), MONTE ROSA THERAPEUTICS INC (GLUE) and REPLIMUNE GROUP INC (REPL). The fund showed a lot of confidence in some stocks as they added substantially to BRIDGEBIO ONCOLOGY THERAPEUT, LYELL IMMUNOPHARMA INC (LYEL) and 4D MOLECULAR THERAPEUTICS IN (FDMT).
Opaleye Management Inc. Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$1.10Billion
as of Aug 14, 2026Opaleye Management Inc. Annual Return Estimates Vs S&P 500
Our best estimate is that Opaleye Management Inc. made a return of 33.08% in the last quarter. In trailing 12 months, it's portfolio return was 99.29%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| immix biopharma inc | 24,177,000 |
| monte rosa therapeutics inc | 18,029,000 |
| replimune group inc | 15,331,900 |
| verastem inc | 6,876,000 |
| phathom pharmaceuticals inc | 2,013,640 |
| inhibrx biosciences inc | 1,922,570 |
| hemab therapeutics hldgs inc | 1,750,260 |
| first tracks biotherapeutics | 1,307,800 |
New stocks bought by Opaleye Management Inc.
Additions
| Ticker | % Inc. |
|---|---|
| bridgebio oncology therapeut | 1,213 |
| lyell immunopharma inc | 334 |
| 4d molecular therapeutics in | 197 |
| cabaletta bio inc | 179 |
| disc medicine inc | 103 |
| editas medicine inc | 100 |
| meiragtx hldgs plc | 67.2 |
| alpha cognition inc | 13.02 |
Additions to existing portfolio by Opaleye Management Inc.
Reductions
| Ticker | % Reduced |
|---|---|
| cg oncology inc | -81.24 |
| sanuwave health inc | -68.8 |
| jade biosciences inc | -66.09 |
| journey med corp | -63.54 |
| atea pharmaceuticals inc | -27.15 |
| annexon inc | -26.47 |
| q32 bio inc | -25.89 |
| biodesix inc | -24.38 |
Opaleye Management Inc. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| perspective therapeutics inc | -19,494,800 |
| protalix biotherapeutics inc | -737,800 |
| assertio holdings inc | -5,064,380 |
| sutro biopharma inc | -4,749,620 |
| nextcure inc | -1,507,810 |
| tectonic therapeutic inc | -3,801,930 |
| rigel pharmaceuticals inc | -1,892,800 |
| lb pharmaceuticals inc | -357,718 |
Opaleye Management Inc. got rid off the above stocks
Sector Distribution
Opaleye Management Inc. has about 76.9% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 76.9 |
| Others | 23.1 |
Market Cap. Distribution
Opaleye Management Inc. has about 1.7% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- MID-CAP
- UNALLOCATED
- MICRO-CAP
- LARGE-CAP
| Category | % |
|---|---|
| SMALL-CAP | 45.9 |
| MID-CAP | 25 |
| UNALLOCATED | 23.1 |
| MICRO-CAP | 4.2 |
| LARGE-CAP | 1.7 |
Stocks belong to which Index?
About 59.8% of the stocks held by Opaleye Management Inc. either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 59.8 |
| Others | 40.2 |
Opaleye Management Inc. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Opaleye Management Inc.
Opaleye Management Inc. has 58 stocks in it's portfolio. About 64.8% of the portfolio is in top 10 stocks. RYTM proved to be the most loss making stock for the portfolio. LQDA was the most profitable stock for Opaleye Management Inc. last quarter.
$1.10BTotal Value
66.00Positions
14 Aug, 2026Last Reported
| Expand | Holdingsorted ascending | % Portfolio | Shares Held | $ Value | % Change |
|---|---|---|---|---|---|
 ADCT Adc Therapeutics SaAdc Therapeutics SaADCT | 0.07% | 700,000 | $749.0K 0.07% | Newnew position | |
 Annexon Inc Annexon IncANNX Opaleye Management Inc.'s holding in Annexon Inc over time | 0.89% | 1,714,450 | $9.79M 0.89% | 26.47%decreased 26.47 percentreduced | |
 Assertio Holdings Inc Opaleye Management Inc.'s holding in Assertio Holdings Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Atea Pharmaceuticals Inc Opaleye Management Inc.'s holding in Atea Pharmaceuticals Inc over time | 0.1% | 235,000 | $1.09M 0.1% | 27.15%decreased 27.15 percentreduced | |
 Jade Biosciences Inc Opaleye Management Inc.'s holding in Jade Biosciences Inc over time | 0.29% | 145,000 | $3.22M 0.29% | 66.09%decreased 66.09 percentreduced | |
 Biodesix Inc Biodesix IncBDSX Opaleye Management Inc.'s holding in Biodesix Inc over time | 0.37% | 180,000 | $4.06M 0.37% | 24.38%decreased 24.38 percentreduced | |
 Cabaletta Bio Inc Opaleye Management Inc.'s holding in Cabaletta Bio Inc over time | 1.09% | 3,863,800 | $12.02M 1.09% | 179.99%increased 179.99 percentadded | |
 Codexis Inc Codexis IncCDXS Opaleye Management Inc.'s holding in Codexis Inc over time | 1.39% | 6,785,000 | $15.33M 1.39% | 0%unchanged 0 percentunchanged | |
 Journey Med Corp Journey Med CorpDERM Opaleye Management Inc.'s holding in Journey Med Corp over time | 0.22% | 350,000 | $2.48M 0.22% | 63.54%decreased 63.54 percentreduced | |
 Editas Medicine Inc Opaleye Management Inc.'s holding in Editas Medicine Inc over time | 1.13% | 3,861,930 | $12.51M 1.13% | 100.41%increased 100.41 percentadded | |
 Enanta Pharmaceuticals Inc Opaleye Management Inc.'s holding in Enanta Pharmaceuticals Inc over time | 0.16% | 125,000 | $1.82M 0.16% | 0%unchanged 0 percentunchanged | |
 Eton Pharmaceuticals Inc Opaleye Management Inc.'s holding in Eton Pharmaceuticals Inc over time | 9.38% | 2,860,000 | $103.53M 9.38% | 0%unchanged 0 percentunchanged | |
 Edgewise Therapeutics Inc Opaleye Management Inc.'s holding in Edgewise Therapeutics Inc over time | 1.84% | 500,000 | $20.32M 1.84% | 0%unchanged 0 percentunchanged | |
 Fortress Biotech Inc Opaleye Management Inc.'s holding in Fortress Biotech Inc over time | 0.25% | 890,000 | $2.72M 0.25% | 14.59%decreased 14.59 percentreduced | |
 4d Molecular Therapeutics In Opaleye Management Inc.'s holding in 4d Molecular Therapeutics In over time | 0.4% | 334,437 | $4.45M 0.4% | 197.83%increased 197.83 percentadded | |
 Monte Rosa Therapeutics Inc Opaleye Management Inc.'s holding in Monte Rosa Therapeutics Inc over time | 1.63% | 745,000 | $18.03M 1.63% | Newnew position | |
 Harrow Inc Harrow IncHROW Opaleye Management Inc.'s holding in Harrow Inc over time | 9.23% | 2,400,000 | $101.93M 9.23% | 15.26%decreased 15.26 percentreduced | |
 Immix Biopharma Inc Opaleye Management Inc.'s holding in Immix Biopharma Inc over time | 2.19% | 2,345,000 | $24.18M 2.19% | Newnew position | |
 Pasithea Therapeutics Corp Opaleye Management Inc.'s holding in Pasithea Therapeutics Corp over time | 0.1% | 2,050,000 | $1.06M 0.1% | Newnew position | |
 Liquidia Corporation Opaleye Management Inc.'s holding in Liquidia Corporation over time | 17.67% | 2,447,500 | $195.14M 17.67% | 3.83%decreased 3.83 percentreduced | |